Q-omics provides the consensus-scored MAPK15 profile across patient tissues and cancer cell-line models. MAPK15 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MAPK15 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, MAPK15 RNA expression shows 14,040 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight COAD, and KIRP as cancer lineages where MAPK15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPK15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPK15 survival associations across molecular data types. MAPK15 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPK15 RNA expression–survival associations across cancer types. High MAPK15 expression shows unfavorable associations in COAD, ACC, PRAD and LGG, but favorable associations in HNSC and KIRP. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for MAPK15 RNA expression.
This table summarizes MAPK15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MAPK15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPK15 shows lower tumor expression in KICH and higher tumor expression in COAD, STAD, KIRC, BLCA and BRCA. The COAD box plot shows higher MAPK15 RNA expression in tumor versus normal tissue (log2 FC = +3.278, t-test p < 0.001).
This table shows molecular features associated with MAPK15 in patient tissues and cancer cell lines. In patient samples, MAPK15 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, MAPK15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
